IKT

Inhibikase Therapeutics (IKT)

Inhibikase Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:IKT

1 2 3 4 5 6 7 8 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/12/06	14:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/12/06	06:50	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/12/06	06:47	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/12/03	20:24	Edgar (US Regulatory)	Form S-3/A - Registration statement under Securities Act of 1933: [Amend]	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/11/19	06:49	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/11/19	06:05	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/11/14	22:30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/11/09	06:07	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/10/29	06:26	Edgar (US Regulatory)	Form SC 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/10/29	05:00	Edgar (US Regulatory)	Form SC 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/10/26	06:52	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/10/26	06:50	Edgar (US Regulatory)	Form SC 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/10/24	08:58	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/10/24	08:53	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/10/24	08:49	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/10/24	08:40	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/10/24	08:38	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/10/24	08:35	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/10/18	08:00	Edgar (US Regulatory)	Form SC 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/10/18	05:05	Edgar (US Regulatory)	Form SC 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/10/11	06:31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/10/09	21:40	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/08/15	05:25	GlobeNewswire Inc.	Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/08/15	05:14	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/08/07	21:00	GlobeNewswire Inc.	Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/07/19	06:23	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/07/19	06:18	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/06/19	06:27	Edgar (US Regulatory)	Form S-1 - General form for registration of securities under the Securities Act of 1933	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/06/17	21:05	GlobeNewswire Inc.	Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201’ Trial Evaluating Risvodetinib in Untreated Parkinson’s Disease	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/06/11	05:20	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:IKT	Inhibikase Therapeutics Inc